source
- FDA approves Revolution Medicines' daraxonrasib for second-line pancreatic cancerThe U.S. Food and Drug Administration announced approval of Revolution Medicines' drug daraxonrasib for patients with pancreatic cancer who have already received prior therapy. The approval marks…
- Haisco licenses inflammatory disease candidate to US startup Sentivera; ViiV's HIV drug cleared for newbornsHaisco Pharmaceutical announced that it has granted a license to US biotech Sentivera for the ex‑China rights to an unnamed inflammatory‑disease candidate. The agreement gives Sentivera the ability…